Study guide
Blood and Marrow Transplant Foundations
OCN Oncology Certified Nurse Study Guide Exam
Track your progress as you read
Finished sections get a check mark.
1 Chapter 1: OCN Exam Orientation and Official Source Control
Official Sources and Credential Purpose Eligibility, Application, and Fees Exam Format, Scoring, Blueprint, and Generic Drugs PSI Scheduling, ATT, Test Day, and Results Blueprint-Based Study Plan and Readiness
2 Chapter 2: Care Continuum, Prevention, Survivorship, and End-of-Life Care
Health Promotion, Risk Reduction, and Epidemiology Screening, Early Detection, and High-Risk Referrals Navigation, Coordination, and Care Continuity Palliative Care, Advance Care Planning, and Goals Survivorship, Rehabilitation, Recurrence, and Late Effects Sexuality, Family Support, Discrimination, and Social Needs End-of-Life Care, Hospice, Bereavement, and Comfort Measures
3 Chapter 3: Oncology Science and Site-Specific Cancer Assessment
Carcinogenesis, Immunology, and Cancer Biology Genomic, Genetic Testing, and Biomarker Literacy Clinical Trials, Research Protocols, and Informed Participation Diagnostic Workup, Biopsy, Imaging, and Pathology Basics Staging, Grading, Prognosis, and Performance Status Common Cancer Patterns and Metastatic Sites Oncology Assessment, Data Clustering, and Escalation
4 Chapter 4: Professional Oncology Nursing Practice, Safety, and Standards
Scope, Standards, Nursing Process, and Documentation Collaboration, Communication, and Interprofessional Practice Safe Handling, PPE, Occupational Health, and Exposure Response Culturally Congruent Care, Advocacy, and Ethics Self-Care, Compassion Fatigue, Burnout, and Professional Development
5 Chapter 5: Treatment Modalities I - Surgery, Radiation, Transplant, Localized and Oral Therapy
Surgery and Procedural Oncology Nursing Care Radiation Therapy Principles, Toxicities, and Teaching Blood and Marrow Transplant Foundations Localized Therapy: Intrathecal, Intravesical, and Regional Care Oral Oncology Therapy Adherence, Safety, and Education Treatment Sequencing, Response Monitoring, and Care Coordination Modality-Specific Patient Teaching and Documentation
6 Chapter 6: Treatment Modalities II - Systemic Therapy, Immunotherapy, and Targeted Agents
Chemotherapy Foundations and Infusion Safety Biotherapy, Immunotherapy, and Immune-Related Adverse Events Targeted Therapy, Immune Cell, and Bispecific Antibody Basics Hormonal Therapy and Endocrine Cancer Treatment Considerations Vascular Access, Infusion Monitoring, and Extravasation Prevention Systemic Therapy Patient Education and Home Safety Therapy Response, Adherence, and Toxicity Escalation
7 Chapter 7: Symptom Management and Supportive Care
Symptom Assessment, Toxicity Grading, and Prioritization Hematologic, Immunologic, and Infection Supportive Care GI, GU, Nutrition, and Hydration Supportive Care Integumentary, Ostomy, Lymphedema, and Wound Care Respiratory, Cardiovascular, Neurologic, and Musculoskeletal Symptoms Pain Management, Pharmacologic, and Integrative Care Vascular Access Device Care and Supportive Care Coordination
8 Chapter 8: Oncologic Emergencies and Rapid Escalation
Sepsis, SIRS, Neutropenic Infection, and Shock Tumor Lysis, Hypercalcemia, SIADH, and Metabolic Emergencies Hypersensitivity, Anaphylaxis, and Infusion Reactions Spinal Cord Compression, SVC Syndrome, Increased ICP, and Obstructions DIC, VTE, Bleeding, and Thrombotic Emergencies Pneumonitis, Extravasation, and Local Therapy Emergencies Immune-Related Emergencies, CRS, ICANS, and Urgent Triage
9 Chapter 9: Psychosocial Dimensions of Oncology Care
Distress Screening, Emotional Response, and Crisis Care Cultural, Spiritual, Religious, and Language-Responsive Care Family, Caregiver Support, and Shared Decision-Making Sexuality, Fertility, Gender, and Body Image Concerns Learning Barriers, Health Literacy, and Patient Education Financial Toxicity, Support Systems, and Resource Referrals
10 Chapter 10: Mixed OCN Case Labs
New Diagnosis Navigation and Treatment Planning Case Lab Chemotherapy Infusion Reaction and Extravasation Case Lab Immunotherapy Toxicities and CRS ICANS Case Lab Radiation Surgery and Localized Therapy Case Lab Symptom Management Neutropenia Pain and Nutrition Case Lab Oncologic Emergency TLS SVC Cord Compression Case Lab Survivorship Palliative Psychosocial and Discharge Case Lab
11 Chapter 11: Final Review, High-Yield Tables, and OCN Exam-Day Readiness
Blueprint Quick Reference and Domain Triage High-Yield Oncology Safety and Emergency Tables Generic Drug Stems, Labs, and Supportive Care Patterns Final Week Practice Plan, Error Log, and Stamina Final 48 Hours, PSI Test Day, and Retake Planning
Blood and Marrow Transplant Foundations
Key Takeaways Explain This Topic AI
Autologous transplant rescues the patient with their own cells after high-dose therapy; allogeneic uses donor cells and adds graft-versus-host disease (GVHD) and graft-versus-tumor effect.
DMSO-cryopreserved infusions can cause garlic odor, flushing, nausea, bradycardia, and blood-pressure swings; the nurse monitors closely during infusion.
Neutrophil engraftment is defined as ANC at or above 500/mm3 for three consecutive days; immune reconstitution lags far behind count recovery.
Acute GVHD targets skin, gut, and liver (rash, diarrhea, rising bilirubin) and is graded by stage and overall grade; chronic GVHD resembles autoimmune disease.
Conditioning-related complications include sinusoidal obstruction syndrome (VOD), hemorrhagic cystitis (cyclophosphamide), TA-TMA, and CMV reactivation.
Last updated: October 2026
Blood and Marrow Transplant Foundations
Blood and marrow transplant (BMT) , also called hematopoietic stem cell transplant (HSCT) , treats hematologic malignancies (leukemia, lymphoma, myeloma) and some nonmalignant disorders. The trajectory: evaluation, conditioning , cell infusion (day 0) , the cytopenic nadir , engraftment , discharge prep, frequent monitoring, and long-term follow-up. It is a multi-week high-risk process, not a single day. OCN items focus on distinguishing transplant types, infusion safety, neutropenic-fever urgency, and GVHD recognition.
Major transplant types
Type Cell source Key concept Nursing emphasis
Autologous Patient's own cells Rescue after high-dose therapy; NO GVHD Mucositis, infection, cytopenias, relapse risk
Allogeneic (myeloablative) Related, unrelated, or cord donor Donor immune system; graft-versus-tumor and GVHD GVHD, immunosuppression, infection prevention
Reduced-intensity (RIC) Donor cells, lighter conditioning Relies on graft-versus-tumor effect Mixed chimerism, delayed GVHD, infection
Conditioning (high-dose chemotherapy with or without total body irradiation) eradicates disease, suppresses the recipient immune system to allow donor engraftment, and creates marrow space. The nurse administers supportive medications per order and watches for mucositis, nausea/vomiting, diarrhea, hemorrhagic cystitis (cyclophosphamide - mesna and hydration are protective), and renal, hepatic, pulmonary, cardiac, or neurologic toxicity.
Cell infusion and the nadir
Stem cell infusion resembles a blood-product transfusion but is a major milestone for families. The nurse verifies patient identity, product data, premedications, emergency readiness, vitals, and central line patency. Cryopreserved autologous products contain dimethyl sulfoxide (DMSO) , which causes a garlic/creamed-corn odor , nausea, flushing, throat irritation, and - watch for these - bradycardia and blood-pressure swings (both hyper- and hypotension) ; rare anaphylaxis. Monitor vitals closely and report changes.
After conditioning the patient enters the nadir : neutropenia, anemia, and thrombocytopenia. Infection prevention is central, and fever in neutropenia is an emergency even when the patient looks well (a single temperature of 38.3 C or higher, or 38.0 C or higher for one hour with ANC below 500/mm3). Assess temperature trends, chills, line-site change, cough, dyspnea, oral lesions, urinary and abdominal symptoms, skin lesions, mental status, and hemodynamics. Thrombocytopenia: epistaxis, petechiae, gum bleeding, hematuria, melena, headache, neurologic change. Anemia: dyspnea, dizziness, chest discomfort, activity intolerance.
Engraftment and complications
Engraftment means the graft is producing blood cells; neutrophil engraftment is defined as an ANC at or above 500/mm3 for three consecutive days , platelet engraftment somewhat later. Rising counts are encouraging, but immune reconstitution takes months to over a year , especially after allogeneic transplant on immunosuppression.
Graft-versus-host disease (GVHD) occurs only in allogeneic transplant, when donor immune cells attack recipient tissues:
GVHD type Target organs Hallmark findings
Acute (classically within 100 days) Skin, gastrointestinal tract, liver Maculopapular rash, voluminous diarrhea, rising bilirubin
Chronic (later, autoimmune-like) Skin, eyes, mouth, lungs, liver, joints, genitals Sclerosis, dry eyes/mouth, bronchiolitis obliterans
Acute GVHD is staged by skin/liver/gut involvement and assigned an overall grade I-IV. Teach patients to report rash, new diarrhea, jaundice, dry/gritty eyes, oral sensitivity, skin tightening, cough, dyspnea, or reduced range of motion. Other complications: sinusoidal obstruction syndrome / veno-occlusive disease (VOD) (weight gain, right-upper-quadrant pain, jaundice, hepatomegaly), transplant-associated thrombotic microangiopathy (TA-TMA), idiopathic pneumonia syndrome, CMV and fungal reactivation , central line infection, relapse, infertility, endocrine dysfunction, bone loss, and secondary malignancy.
The RN trends and escalates rather than diagnoses.
Discharge and long-term teaching
Discharge readiness is practical. Key points:
Report fever exactly as instructed; do not self-treat with antipyretics that mask fever.
Avoid sick contacts; follow neutropenic-diet/food-safety and hand-hygiene instructions.
Take immunosuppressants (calcineurin inhibitors) consistently; never stop abruptly.
Report diarrhea, rash, jaundice, cough, dyspnea, bleeding, confusion, or decreased intake.
Follow the revaccination schedule - transplant erases prior childhood immunity, so the series restarts roughly 6-12 months post-transplant per protocol.
Document symptom assessment, line status, intake/output, mucositis grade, transfusion response, education, caregiver participation, and barriers.
Supportive care during the nadir
Nursing care during cytopenia is protocol-driven. Neutropenic precautions include strict hand hygiene, often a private room with high-efficiency filtration, a low-microbial or neutropenic diet per policy, no fresh flowers or standing water, and screening of visitors for illness. Growth factors such as filgrastim may be ordered to speed neutrophil recovery; the nurse teaches that bone pain is a common, expected side effect.
Transfusion support is frequent: cellular blood products for transplant recipients are typically irradiated to prevent transfusion-associated GVHD and leukoreduced, and CMV-safe products are used for CMV-negative patients. Mucositis from conditioning is graded and managed with bland rinses, scheduled analgesia (often patient-controlled opioids), and parenteral nutrition when oral intake fails.
Common discharge teaching points include: report fever exactly as instructed and do not mask it with antipyretics; avoid crowds, sick contacts, gardening, and pet waste; follow food-safety rules; take immunosuppressants and antimicrobial prophylaxis on schedule; and return for the frequent labs and chimerism testing that track engraftment.
CAR T-cell therapy: a related cellular platform
The OCN exam increasingly references chimeric antigen receptor (CAR) T-cell therapy , an autologous cellular product engineered to target the malignancy. Its signature toxicities are distinct from transplant. Cytokine release syndrome (CRS) presents with fever, hypotension, hypoxia, and tachycardia, typically within the first days, and is treated with supportive care and the interleukin-6 blocker tocilizumab per protocol. Immune effector cell-associated neurotoxicity syndrome (ICANS) presents with confusion, aphasia, tremor, handwriting deterioration, and seizures, and is monitored with a standardized encephalopathy assessment.
Nurses perform frequent neuro and vital-sign checks and escalate fever or any new confusion immediately, since both syndromes can progress rapidly.
Counts recover before stamina, immunity, nutrition, fertility, employment, and emotional recovery, so survivorship teaching addresses fatigue, sexual health, secondary-cancer surveillance, bone density, and the long revaccination timeline. Vigilance over weeks to months, not a single day, defines transplant nursing.